Trial Profile
A Prospective, Randomized, Double‑Blinded, Vehicle‑ and Placebo-Controlled, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of IDCT in Subjects With Single‑Level, Symptomatic Lumbar Intervertebral Disc Degeneration
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 27 Jan 2023
Price :
$35
*
At a glance
- Drugs Rebonuputemcel (Primary) ; Hyaluronic acid
- Indications Intervertebral disc degeneration
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors DiscGenics
- 27 Jan 2023 According to a DiscGenics media release, US FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Injectable Disc Cell Therapy (IDCT) for degenerative disc disease.
- 23 Jan 2023 According to a DiscGenics media release, data presented at 41st Annual J.P. Morgan Healthcare Conference.
- 23 Jan 2023 According to a DiscGenics media release, data presented at the North American Spine Society (NASS) 37th Annual Meeting .